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1 diabetes overall; probably, at least to some de-
gree, it is iatrogenic and due to overinsuliniza-
tion, hypoglycemia generation, or lack of proper 
education. The Diabetes Control and Complica-
tions Trial/Epidemiology of Diabetes Interven-
tions and Complications Study (DCCT/EDIC)8 has 
shown that excess weight gain in DCCT was asso-
ciated with sustained increases in central obesi-
ty, IR, dyslipidemia, and blood pressure, as well 
as more extensive atherosclerosis during EDICT.8 
Other factors that may influence IR in type 1 dia-
betes patients include a family history of type 2 
diabetes, chronic hyperglycemia (glucotoxicity), 
age, ethnicity, physical activity, and drug use.9 
The presence of different degree of IR as part of 
clinical picture of latent autoimmune diabetes in 
adults) is one of the arguments to postulate re-
classification of diabetes.
However,  the problem of IR in type 1 diabetes 
requires further investigation including studies on 
a relative distribution of the resistance to insulin 
among different organs and tissues. It was recent-
ly shown, for example, that in patients with type 
1 diabetes who naturally lack the portal/periph-
eral insulin gradient, insulin stimulation of he-
patic lipogenesis may be diminished. That would 
protect type 1 diabetes individuals against the 
development of nonalcoholic fatty liver disease 
and hepatic IR.10
IR is a well-established risk factor for cardio-
vascular disease.11,12 It has been suggested that 
for type 1 diabetes individuals, IR-related fac-
tors, not the glycemic control, may be crucial in 
the development of cardiovascular events.11,12 
Furthermore, it has been shown that in patients 
with type 1 diabetes, sex differences in IR-asso-
ciated fat deposition and distribution of high-
density lipoprotein (HDL) and low-density lipo-
protein (LDL) cholesterols may explain why dia-
betes increases coronary calcification in women 
relatively more than in men.12
Type 1 diabetes mellitus results from autodestruc-
tion of pancreatic β-cells and is characterized by 
absolute insulin deficiency. Thus, the therapy of 
type 1 diabetes must be based on insulin replace-
ment. However, despite the development of more 
physiological strategies of exogenous insulin de-
livery, including the use of advanced technologies 
such as insulin pumps or systems of continuous 
glucose monitoring, the treatment of type 1 dia-
betes remains an ongoing challenge. Even when 
the glycemic goals are reached, the life expectan-
cy among type 1 diabetes patients is shorter than 
that in age-matched healthy individuals.1
There is no doubt that the risk of cardiovascu-
lar disease in type 1 diabetes is significantly in-
creased.1,2 There may be many reasons for this, in-
cluding hyperglycemia per se,2 hypoglycemic epi-
sodes,3 nonphysiological insulin delivery,4 while 
the role of blood glucose variability is less estab-
lished.3 The alarming data have come from pe-
diatric populations. It was shown that despite 
short disease duration, intensive insulin treat-
ment, fair glycemic control, and no signs of mi-
crovascular complications, children and adoles-
cents with type 1 diabetes had slightly increased 
carotid artery intima–media thickness (IMT) com-
pared with healthy control subjects.5 
Recently, the interest in the role of insulin re-
sistance (IR) in type 1 diabetes has grown. IR is 
often observed in patients with type 1 diabetes 
during the natural history of adolescence and pu-
berty and during intercurrent illness; however, it 
is now well established that diminished sensitiv-
ity to insulin may be a common feature of type 1 
diabetes irrespectively of patients’ age or current 
health status.6 One of the first data showing that 
increased IR is typical not only for type 2 diabe-
tes but also for type 1 diabetes patients were re-
ported by DeFronzo et al7 more than 30 years ago, 
confirmed by many other groups later on. IR in 
type 1 diabetes may also be worsened by weight 
gain. Unfortunately, obesity is increasing in type 
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Thus, the question arises as to whether IR is 
present in type 1 diabetes patients (or at least in 
some subgroups) and whether it is a key factor 
increasing the risk of cardiovascular events. Can 
we treat IR in type 1 diabetes patients in the same 
way as we do it in those with type 2 diabetes? Can 
metformin be effective and safe in patients with 
type 1 diabetes? If so, what is the mechanism of 
metformin-related cardiovascular protection in 
type 1 diabetes patients?
Some of these issues have already been ad-
dressed. It has been shown in a well-designed ran-
domized study that metformin improves endothe-
lial function in patients with type 1 diabetes.13A 
meta-analysis published recently has shown that 
when used in type 1 diabetes patients, metfor-
min was associated with a reduction in daily in-
sulin dosage, body weight, and total cholesterol, 
LDL cholesterol, and HDL cholesterol levels. Of 
note, no significant difference was found between 
the metformin and placebo groups in the risk of 
severe hypoglycemia or diabetic ketoacidosis.14
Burchardt et al15 studied the relationship be-
tween the metformin usage and lipid profile and 
assessed the influence of metformin therapy on 
carotid IMT in type 1 diabetes patients with excess 
body fat.15 Of note, in their analysis, they includ-
ed the measurement of the activity of 2 enzymes 
involved in LDL oxidization, lipoprotein-associ-
ated phospholipase A2 (Lp-PLA2), and cholester-
yl ester lipase.
The authors have found that the use of met-
formin resulted in significant reductions in IMT 
of the carotid artery and glycated LDL. Of inter-
est, glycated LDL inversely correlated with the 
Lp-PLA2 concentration in patients receiving met-
formin. These findings require further investiga-
tion but they may contribute to the explanation 
of antiatherosclerotic properties of metformin.
The study contributes to the discussion con-
cerning the need of taking under consideration 
the complex phenotype of type 1 diabetes when 
choosing optimal treatment strategies for pa-
tients. This discussion may be relevant also for 
other types of diabetes, traditionally seen as aris-
ing from pancreatic β-cell failure only. We have 
shown the presence of IR features in Permanent 
Neonatal Diabetes Mellitus (PNDM), in individ-
uals with mutations in genes encoding the sub-
units of pancreatic β-cell ATP-dependent potas-
sium channel (ABCC8 and KNCJ11).16,17
To conclude, we are probably in the advent of 
revisiting treatment dogmas in diabetes. The need 
for IR treatment may be much more common than 
we used to believe, and metformin should be con-
sidered as adjunctive therapy in many more so 
far “not obvious” clinical situations in diabetes. 
However, the longitudinal studies are needed to 
elucidate the potential relationship between met-
formin use and protection from vascular dam-
age in diabetes resulting primarily from pancre-
atic β-cell failure.
